OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
FLNA$1.2458

Filana Therapeutics Inc

Biotechnology & Medical ResearchVerified

Filana Therapeutics Inc has a strong liquidity position, with a current ratio of 4.07 and cash and equivalents amounting to $207.29 million, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.0, reflecting no long-term debt and a capital structure that is entirely equity-funded. This liquidity position is further supported by a free cash flow of $6.43 million, despite an operating cash flow of -$37.37 million. In terms of profitability, the company reported a net income of $6.16 million and an operating income of -$61.40 million, resulting in a return on equity of 3.26% and a return on assets of 2.53%. These figures suggest that while the company is generating positive net income, it is experiencing significant operating losses, which may impact its long-term profitability and sustainability. Filana Therapeutics Inc's revenue concentration and geographic exposure are not explicitly detailed in the available data, making it difficult to assess the company's segment and geographic diversification. However, the absence of detailed segment data implies that the company's operations may be concentrated in a single business line or geographic region, which could pose concentration risks. The company's growth trajectory is not clearly defined in the available data, as there are no specific numeric deltas or revenue history provided to indicate the direction of growth for the current or next fiscal year. The lack of detailed growth metrics makes it challenging to assess the company's future performance and expansion potential. Risk factors for Filana Therapeutics Inc include a low liquidity risk, as indicated by the strong current ratio and substantial cash reserves. However, the company's dilution potential could not be assessed due to missing basic and diluted share counts. This uncertainty may affect investor confidence and the company's ability to raise capital without diluting existing shareholders. Recent events and filings for Filana Therapeutics Inc are not detailed in the available data, which limits the ability to provide insights into the company's recent strategic moves or operational developments. The absence of recent events data suggests that the company may not have disclosed significant developments in the near term.

30-day price · FLNA-0.50 (-29.8%)
Low$1.16High$1.80Close$1.18As of17 May, 00:00 UTC
Profile
CompanyFilana Therapeutics Inc
TickerFLNA.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Filana Therapeutics Inc is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of therapeutic products.

Classification. Filana Therapeutics Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Filana Therapeutics Inc has a strong liquidity position, with a current ratio of 4.07 and cash and equivalents amounting to $207.29 million, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.0, reflecting no long-term debt and a capital structure that is entirely equity-funded. This liquidity position is further supported by a free cash flow of $6.43 million, despite an operating cash flow of -$37.37 million. In terms of profitability, the company reported a net income of $6.16 million and an operating income of -$61.40 million, resulting in a return on equity of 3.26% and a return on assets of 2.53%. These figures suggest that while the company is generating positive net income, it is experiencing significant operating losses, which may impact its long-term profitability and sustainability. Filana Therapeutics Inc's revenue concentration and geographic exposure are not explicitly detailed in the available data, making it difficult to assess the company's segment and geographic diversification. However, the absence of detailed segment data implies that the company's operations may be concentrated in a single business line or geographic region, which could pose concentration risks. The company's growth trajectory is not clearly defined in the available data, as there are no specific numeric deltas or revenue history provided to indicate the direction of growth for the current or next fiscal year. The lack of detailed growth metrics makes it challenging to assess the company's future performance and expansion potential. Risk factors for Filana Therapeutics Inc include a low liquidity risk, as indicated by the strong current ratio and substantial cash reserves. However, the company's dilution potential could not be assessed due to missing basic and diluted share counts. This uncertainty may affect investor confidence and the company's ability to raise capital without diluting existing shareholders. Recent events and filings for Filana Therapeutics Inc are not detailed in the available data, which limits the ability to provide insights into the company's recent strategic moves or operational developments. The absence of recent events data suggests that the company may not have disclosed significant developments in the near term.
Key takeaways
  • Filana Therapeutics Inc has a strong liquidity position with a current ratio of 4.07 and substantial cash reserves.
  • The company is generating positive net income but is experiencing significant operating losses, which may impact long-term profitability.
  • The company's capital structure is entirely equity-funded, with no long-term debt.
  • The company's growth trajectory and revenue concentration are not clearly defined in the available data.
  • The company's dilution potential could not be assessed due to missing share count data.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's operating margin is negative, indicating a need to improve operational efficiency to enhance profitability.
  • **rd_outlook_rationale**: The company's R&D outlook is not explicitly detailed, but the focus on pharmaceuticals and medical research suggests ongoing investment in innovation.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income-$61.4M
Net income$6.2M
R&D
SG&A
D&A
SBC
Operating cash flow-$37.4M
CapEx-$29.0k
Free cash flow$6.4M
Total assets$243.6M
Total liabilities$54.6M
Total equity$189.0M
Cash & equivalents$207.3M
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$32.9M-$32.4M-$54.1M
FY-3-$80.0M-$76.2M-$77.7M
FY-2-$106.0M-$97.2M-$96.1M
FY-1-$141.4M-$24.3M-$23.3M
FY0-$95.4M-$91.0M-$90.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$266.8M$253.9M$233.4M
FY-3$234.8M$227.5M$201.0M
FY-2$151.7M$137.5M$121.1M
FY-1$157.5M$145.7M$128.6M
FY0$118.4M$74.4M$95.5M
PeriodOCFCapExFCFSBC
FY-4-$30.2M-$22.2M-$54.1M
FY-3-$77.5M-$2.7M-$77.7M
FY-2-$82.0M-$414.0k-$96.1M
FY-1-$116.9M-$103.0k-$23.3M
FY0-$32.3M-$581.0k-$90.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7-$61.4M$6.2M$6.4M
FQ-6-$30.6M-$27.9M-$27.7M
FQ-5-$29.5M-$27.6M-$27.4M
FQ-4-$24.6M-$23.4M-$23.2M
FQ-3-$45.4M-$44.2M-$44.0M
FQ-2-$11.9M-$10.8M-$10.7M
FQ-1-$13.6M-$12.5M-$12.7M
FQ0-$11.2M-$10.3M-$10.1M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$243.6M$189.0M$207.3M
FQ-6$223.8M$166.6M$149.0M
FQ-5$157.5M$145.7M$128.6M
FQ-4$140.9M$127.6M$117.3M
FQ-3$135.4M$88.0M$112.4M
FQ-2$129.7M$81.6M$106.1M
FQ-1$118.4M$74.4M$95.5M
FQ0$108.4M$68.1M$86.6M
PeriodOCFCapExFCFSBC
FQ-7-$37.4M-$29.0k$6.4M
FQ-6-$55.7M-$46.0k-$27.7M
FQ-5-$116.9M-$103.0k-$27.4M
FQ-4-$11.3M$0.00-$23.2M
FQ-3-$16.3M$0.00-$44.0M
FQ-2-$22.5M-$80.0k-$10.7M
FQ-1-$32.3M-$581.0k-$12.7M
FQ0-$8.9M-$10.1M
Valuation
Market price$1.24
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$189.0M
Net cash$207.3M
Current ratio4.1
Debt/Equity0.0
ROA2.5%
ROE3.3%
Cash conversion-6.1%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio
Risk assessment
Dilution riskUnknown
Liquidity riskLow
  • Dilution risk could not be assessed (basic + diluted share counts missing).
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricFLNAActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity0.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Observations
IR observations
market data ESG Score20.02 (0-100, higher is better)
Environment pillar0 (0-100)
Social pillar29.70 (0-100)
Governance pillar24.54 (0-100)
ESG controversies score23.97 (0-100, higher = fewer controversies)
ESG gradeD+
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-17 00:42 UTC#8c07c302
Market quoteclose USD 1.36
no public URL
2026-05-17 00:42 UTC#a2ee65e6
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 23:04 UTCJob: bafddf96